
AIM ImmunoTech AIM
$ 0.11
-8.33%
AIM ImmunoTech Accounts Payables | AIM
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables AIM ImmunoTech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.63 M | 6.38 M | 6.44 M | 377 K | 198 K | 383 K | 472 K | 680 K | 741 K | 887 K | 1.21 M | 2.08 M | 1.27 M | 2.16 M | 1.68 M | 1.33 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.44 M | 198 K | 1.75 M |
Quarterly Accounts Payables AIM ImmunoTech
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 443 K | 480 K | 1.22 M | 1.63 M | 1.25 M | 7.3 M | 6.94 M | 6.38 M | 6.26 M | 5.46 M | 6.57 M | 6.44 M | 2.79 M | 2.15 M | - | 377 K | 957 K | 712 K | 378 K | 198 K | 369 K | 451 K | 189 K | 383 K | 383 K | 383 K | 383 K | 472 K | 472 K | 472 K | 472 K | 680 K | 680 K | 680 K | 680 K | 741 K | 741 K | 741 K | 741 K | 887 K | 887 K | 887 K | 887 K | 1.21 M | 1.51 M | 1.6 M | 2.32 M | 2.08 M | 2.45 M | 1.47 M | 1.22 M | 1.27 M | 1.72 M | 967 K | 1.66 M | 2.16 M | 2.34 M | 1.8 M | 2.46 M | 1.68 M | 1.58 M | 1.12 M | 1.68 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.3 M | 189 K | 1.71 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
PDS Biotechnology Corporation
PDSB
|
3.57 M | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
11.3 M | $ 0.87 | -4.76 % | $ 580 M | ||
|
Phathom Pharmaceuticals
PHAT
|
4.98 M | $ 4.65 | -8.46 % | $ 339 M | ||
|
Gossamer Bio
GOSS
|
5.96 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Liquidia Corporation
LQDA
|
3.68 M | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
MediciNova
MNOV
|
625 K | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
45.5 M | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
651 K | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
Immunome
IMNM
|
3.34 M | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Incyte Corporation
INCY
|
210 M | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
550 K | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Regeneron Pharmaceuticals
REGN
|
939 M | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
28.1 M | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
3.81 M | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
2.9 M | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
986 K | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
20.3 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
2.88 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
3.33 M | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
5.24 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
45.4 M | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
792 K | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
2.6 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
2.03 M | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
18.4 M | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Equillium
EQ
|
755 K | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
579 K | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
7.89 M | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
10.9 M | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
4.29 M | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
13.9 M | $ 112.31 | -3.84 % | $ 7.3 B | ||
|
ADC Therapeutics SA
ADCT
|
9.18 M | $ 1.29 | -2.28 % | $ 164 M | ||
|
Harmony Biosciences Holdings
HRMY
|
17.7 M | $ 32.58 | -1.21 % | $ 1.87 B | ||
|
Ardelyx
ARDX
|
19.2 M | $ 2.99 | -2.25 % | $ 721 M | ||
|
Akebia Therapeutics
AKBA
|
21.2 M | $ 0.39 | -8.41 % | $ 100 M | ||
|
Alector
ALEC
|
1.69 M | $ 2.34 | 1.52 % | $ 241 M | ||
|
ALX Oncology Holdings
ALXO
|
4.91 M | $ 1.06 | 3.43 % | $ 56.9 M | ||
|
Amneal Pharmaceuticals
AMRX
|
166 M | $ 21.12 | -1.26 % | $ 6.62 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
1.17 M | $ 4.03 | -1.11 % | $ 772 M | ||
|
Agenus
AGEN
|
83 M | $ 5.97 | -2.85 % | $ 178 M |